Enavogliflozin for treating diastolic dysfunction in nonobstructive hypertrophic cardiomyopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of enavogliflozin, an SGLT2 inhibitor, on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. It aims to compare the drug's efficacy against a placebo over a 24-week period, focusing on improvements in exercise capacity, symptoms, serum biomarkers, and arrhythmic burden. Participants will be randomly assigned to receive either enavogliflozin or a placebo, with their diastolic function assessed through echocardiography. The study addresses a gap in treatment options for this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. A patient who understands the research protocol and fills out a consent form
2. Adults over 19 years of age and under 80 years of age
3. Non-diabetic or type 2 diabetic patients (HbA1c 6.5-10.5%)
4. Patients with non-obstructive hypertrophic cardiomyopathy who do not show significant dynamic left ventricular outflow tract obstruction at rest or during Valsalva maneuver or exercise stress on echocardiography within 3 months of the screening visit.

   * Non-obstructive hypertrophic cardiomyopathy: corresponds to maximum left ventricular outflow tract pressure gradient \<30mmHg.
   * Maximum left ventricular wall thickness ≥15mm if there is no family history of hypertrophic cardiomyopathy, or maximum left ventricular wall thickness ≥13mm if there is a family history of hypertrophic cardiomyopathy or positive for related genetic mutation.
5. For hypertrophic cardiomyopathy, existing beta blockers, calcium channel blockers, diuretics and Renin-angiotension-system(RAS) blockers (beta-blocker, non-dihydropyridine Calcium Cannel Blocker, loop diuretics, thiazide and thiazide-like diuretics, mineralocorticoid receptor antagonist, angiotensin converting enzyme inhibitor/angiotensin) For patients using receptor blocker/angiotensin receptor neprilysin inhibitor), the drug dose was stable for 2 weeks before screening and no change in dose is expected throughout the study period.
6. Women of childbearing age who agree to use contraception (hormones, intrauterine device, tubal ligation, spouse's vasectomy, etc.) for 30 days from the time of screening, during the clinical trial period, and after taking the clinical trial drug.
7. New York Heart Association (NYHA) Class 1\~3

Exclusion Criteria:

1. History of hypersensitivity to clinical trial drugs
2. If you are currently taking Sodium-glucose transporter 2 (SGLT2) inhibitors or within 4 weeks

   \- For diabetic patients, any type of hypoglycemic agent other than Sodium-glucose transporter 2 (SGLT2) inhibitors can be used.
3. Patients who cannot undergo diastolic stress echocardiography
4. Patients on dialysis or with chronic renal failure with an estimated glomerular filtration rate \<30 mL/min/1.73m2
5. Patients with Cardiac implantable electronic device (CIED)
6. Currently pregnant or lactating
7. ASpartate Transaminase(AST) or ALanine Transaminase(ALT) value more than 3 times the upper limit of normal during liver function test, history of hepatic coma, history of esophageal varices, history of porto-caval anastomosis.
8. Uncontrolled hypertension (SBP≥180mmHg or DBP≥110mmHg) or severe hypotension (SBP\<90mmHg)
9. Severe aortic or mitral stenosis with the possibility of surgery during the clinical trial period
10. Those waiting for a heart transplant or those who have received a heart transplant
11. Persons with diseases that need to be differentiated from heart failure symptoms at the investigator's discretion, such as severe anemia (hemoglobin \<7 g/dL), uncontrolled arrhythmia, severe lung disease, etc.
12. If you have cancer undergoing chemotherapy/radiation/surgical treatment or if your life expectancy is expected to be less than 1 year.
13. Untreated alcohol or drug abuse
14. If you are participating in the administration of another clinical trial drug or clinical trial device test, or have completed participation for less than 30 days.
15. Patients with type 1 diabetes or diabetic ketoacidosis
16. New York Heart Association (NYHA) class 4

Where it's running

• Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Jiwon Seo, MD — Gangnam Severance Hospital

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HTX-001: a first-in-human test to see if this daily shot is safe for adults with nonobstructive hypertrophic cardiomyopathy

  This study tests multiple doses of HTX-001, an injectable antisense therapy, to see if it is safe and how it behaves in the body for adults with nonobstructive hypertrophic cardiomyopathy already on standard care.

  Recruiting at 3 sites Phase 1 Haya Therapeutics, Inc. · Boston, Massachusetts and 2 other locations · NCT07867288

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Autologous adipose-derived stem cell injections for knee osteoarthritis

  We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.

  Recruiting at 3 sites Yonsei University · Incheon and 2 other locations · NCT07901790

• SVF cellular mix, secretome, and knee response in osteoarthritis

  This study tests the cellular composition and secretome of research-only adipose-derived SVF in adults with knee OA who are already planned to receive an autologous SVF injection as part of their care.

  Recruiting Yonsei University · Seoul · NCT07898501

• 2-mm subchondral drilling vs sequential 4-mm and 2-mm drilling during CARTISTEM implantation for knee cartilage defects

  This study tests whether drilling the knee with a 2-mm drill alone works as well as sequential 4-mm then 2-mm drilling when combined with CARTISTEM treatment for medial knee cartilage defects.

  Recruiting Yonsei University · Seoul · NCT07881445

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.